idiopathic%20pulmonary%20fibrosis
IDIOPATHIC PULMONARY FIBROSIS

Idiopathic pulmonary fibrosis is the progressive parenchymal scarring & loss of pulmonary function due to unidentifiable cause of lung injury.

It is a specific form of chronic fibrosing interstitial pneumonia with the histopathologic characteristics of usual interstitial pneumonia.

Approximately 5% of patients are asymptomatic. Common signs and symptoms are exertional dyspnea, nonproductive cough, finger clubbing and bilateral inspiratory crackles.

Surgical Intervention

 Lung Transplantation

  • May be considered in idiopathic pulmonary fibrosis patients with moderate to severe disease
  •  Since idiopathic pulmonary fibrosis is a potentially rapid & progressive disease, the evaluation & opportunity for a transplantation is limited & is much shorter for patients with  idiopathic pulmonary fibrosis
    • Decision to undergo lung transplantation should be made within 3-6 months after initial diagnosis
    • Expected median survival is 34 months & applies after initial diagnosis of idiopathic pulmonary fibrosis
    • Once diagnosed, the patient must be referred immediately to a transplant center for evaluation
  •  A completion of at least 3 months of rehabilitation program is required before the patient may be considered for its eligibility for a transplantation
  • Patients who are 75 years old are still accepted in the transplant program
Acute Exacerbation of Idiopathic Pulmonary Fibrosis
  • Patients with acute exacerbation of idiopathic pulmonary fibrosis do not benefit from lung transplantation as perioperative risks are greater
    • ICU patients or those who are hooked to a mechanical ventilator may be at risk if subjected to a transplantation
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Respirology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
5 days ago
New drug applications approved by US FDA as of 01 - 15 June 2019 which includes New Molecular Entities (NMEs) and new biologics. It does not include Tentative Approvals. Supplemental approvals may have occurred since the original approval date.